<html xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:dt="uuid:C2F41010-65B3-11d1-A29F-00AA00C14882" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type  content="text/html; charset=UTF-8" ><meta name=ProgId  content=Word.Document ><meta name=Generator  content="Microsoft Word 14" ><meta name=Originator  content="Microsoft Word 14" ><link rel=File-List  href="8、全国名中医林毅五十年乳腺癌临证精要（1031周校对）.files/filelist.xml" ><title></title><!--[if gte mso 9]><xml><o:DocumentProperties><o:Author>Administrator</o:Author><o:LastAuthor>独自1388757202</o:LastAuthor><o:Revision>1</o:Revision><o:Pages>7</o:Pages><o:Characters>24449</o:Characters><o:Lines>180</o:Lines><o:Paragraphs>50</o:Paragraphs></o:DocumentProperties><o:CustomDocumentProperties><o:KSOProductBuildVer dt:dt="string" >2052-12.1.0.18608</o:KSOProductBuildVer><o:ICV dt:dt="string" >CF9DC9D084334432B7F1369208B0BB65_13</o:ICV></o:CustomDocumentProperties></xml><![endif]--><!--[if gte mso 9]><xml><o:OfficeDocumentSettings></o:OfficeDocumentSettings></xml><![endif]--><!--[if gte mso 9]><xml><w:WordDocument><w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel><w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEvery><w:DisplayVerticalDrawingGridEvery>2</w:DisplayVerticalDrawingGridEvery><w:DocumentKind>DocumentNotSpecified</w:DocumentKind><w:DrawingGridVerticalSpacing>7.8 磅</w:DrawingGridVerticalSpacing><w:PunctuationKerning></w:PunctuationKerning><w:View>Web</w:View><w:Compatibility><w:AdjustLineHeightInTable/><w:DontGrowAutofit/><w:BalanceSingleByteDoubleByteWidth/><w:DoNotExpandShiftReturn/><w:UseFELayout/></w:Compatibility><w:Zoom>0</w:Zoom></w:WordDocument></xml><![endif]--><!--[if gte mso 9]><xml><w:LatentStyles DefLockedState="false"  DefUnhideWhenUsed="true"  DefSemiHidden="true"  DefQFormat="false"  DefPriority="99"  LatentStyleCount="260" >
<w:LsdException Locked="false"  Priority="0"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="Normal" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="heading 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 7" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 8" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 9" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 7" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 8" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 9" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 7" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 8" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 9" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Normal Indent" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="footnote text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="annotation text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  QFormat="true"  Name="header" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  QFormat="true"  Name="footer" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index heading" ></w:LsdException>
<w:LsdException Locked="false"  Priority="35"  SemiHidden="false"  QFormat="true"  Name="caption" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="table of figures" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="envelope address" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="envelope return" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="footnote reference" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="annotation reference" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="line number" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="page number" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="endnote reference" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="endnote text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="table of authorities" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="macro" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="toa heading" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Bullet" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Number" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Bullet 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Bullet 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Bullet 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Bullet 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Number 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Number 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Number 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Number 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="10"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="Title" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Closing" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Signature" ></w:LsdException>
<w:LsdException Locked="false"  Priority="1"  SemiHidden="false"  QFormat="true"  Name="Default Paragraph Font" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text Indent" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Continue" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Continue 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Continue 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Continue 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Continue 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Message Header" ></w:LsdException>
<w:LsdException Locked="false"  Priority="11"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="Subtitle" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Salutation" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Date" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text First Indent" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text First Indent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Note Heading" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text Indent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text Indent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Block Text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Hyperlink" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="FollowedHyperlink" ></w:LsdException>
<w:LsdException Locked="false"  Priority="22"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="Strong" ></w:LsdException>
<w:LsdException Locked="false"  Priority="20"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="Emphasis" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Document Map" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Plain Text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="E-mail Signature" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Normal (Web)" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Acronym" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Address" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Cite" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Code" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Definition" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Keyboard" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Preformatted" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Sample" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Typewriter" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Variable" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  QFormat="true"  Name="Normal Table" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="annotation subject" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="No List" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="1 / a / i" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="1 / 1.1 / 1.1.1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Article / Section" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Simple 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Simple 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Simple 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Classic 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Classic 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Classic 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Classic 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Colorful 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Colorful 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Colorful 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Columns 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Columns 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Columns 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Columns 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Columns 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 7" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 8" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 7" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 8" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table 3D effects 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table 3D effects 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table 3D effects 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Contemporary" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Elegant" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Professional" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Subtle 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Subtle 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Web 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Web 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Web 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Balloon Text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Table Grid" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Theme" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Placeholder Text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="No Spacing" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="34"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="List Paragraph" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Quote" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Intense Quote" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 6" ></w:LsdException>
</w:LatentStyles></xml><![endif]--><style>
@font-face{
font-family:"Times New Roman";
}

@font-face{
font-family:"宋体";
}

@font-face{
font-family:"Wingdings";
}

@font-face{
font-family:"楷体";
}

@font-face{
font-family:"华文仿宋";
}

@font-face{
font-family:"新宋体";
}

p.MsoNormal{
mso-style-name:正文;
mso-style-parent:"";
margin:0pt;
margin-bottom:.0001pt;
mso-pagination:none;
text-align:justify;
text-justify:inter-ideograph;
font-family:宋体;
mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;
mso-font-kerning:1.0000pt;
}

span.10{
font-family:'Times New Roman';
}

span.15{
font-family:'Times New Roman';
font-size:9.0000pt;
}

span.16{
font-family:'Times New Roman';
font-size:9.0000pt;
}

p.MsoFooter{
mso-style-name:页脚;
mso-style-noshow:yes;
margin:0pt;
margin-bottom:.0001pt;
layout-grid-mode:char;
mso-pagination:none;
text-align:left;
font-family:宋体;
mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;
mso-font-kerning:1.0000pt;
}

p.MsoHeader{
mso-style-name:页眉;
mso-style-noshow:yes;
margin:0pt;
margin-bottom:.0001pt;
layout-grid-mode:char;
mso-pagination:none;
text-align:center;
font-family:宋体;
mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;
mso-font-kerning:1.0000pt;
}

p.19{
mso-style-name:"List Paragraph";
margin:0pt;
margin-bottom:.0001pt;
text-indent:21.0000pt;
mso-char-indent-count:2.0000;
mso-pagination:none;
text-align:justify;
text-justify:inter-ideograph;
font-family:宋体;
mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;
mso-font-kerning:1.0000pt;
}

p.20{
mso-style-name:Revision;
mso-style-noshow:yes;
margin:0pt;
margin-bottom:.0001pt;
font-family:宋体;
mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;
mso-font-kerning:1.0000pt;
}

span.msoIns{
mso-style-type:export-only;
mso-style-name:"";
text-decoration:underline;
text-underline:single;
color:blue;
}

span.msoDel{
mso-style-type:export-only;
mso-style-name:"";
text-decoration:line-through;
color:red;
}

table.MsoNormalTable{
mso-style-name:普通表格;
mso-style-parent:"";
mso-style-noshow:yes;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-padding-alt:0.0000pt 5.4000pt 0.0000pt 5.4000pt;
mso-para-margin:0pt;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-family:'Times New Roman';
font-size:10.0000pt;
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;
}
@page{mso-page-border-surround-header:no;
	mso-page-border-surround-footer:no;}@page Section0{
margin-top:72.0000pt;
margin-bottom:72.0000pt;
margin-left:90.0000pt;
margin-right:90.0000pt;
size:595.3000pt 841.9000pt;
layout-grid:15.6000pt;
mso-header-margin:42.5500pt;
mso-footer-margin:49.6000pt;
}
div.Section0{page:Section0;}</style></head><body style="tab-interval:21pt;text-justify-trim:punctuation;" ><!--StartFragment--><div class="Section0"  style="layout-grid:15.6000pt;" ><p class=MsoNormal  align=center  style="text-indent:32.0000pt;mso-char-indent-count:2.0000;text-align:center;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:16.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >全国名中医林毅五十年乳腺癌临证精要</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:16.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.1000pt;mso-char-indent-count:2.0000;line-height:150%;" ><b><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-weight:bold;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒</font></span></b><b><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-weight:bold;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><o:p></o:p></span></b></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺增生病属于中医药治疗的优势病种，目前临床上大多数从肝论治，常以疏肝解郁、理气活血、化痰软坚为治则，对年轻、病程较短、肝郁气滞型、单纯性乳腺增生病有一定的疗效，但普遍存在着治标有余，治本不足，复发率相对较高，对囊性增生病疗效较差等问题。因此，对乳腺增生病进行研究，寻找理想的防治方案，对缓解疼痛、缩小肿块，改善本病患者的生活质量具有积极重要的现实意义。林毅教授自</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >20<font face="宋体" >世纪</font><font face="Times New Roman" >80</font><font face="宋体" >年</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >代提出乳腺增生病</font><font face="宋体" >“中医药周期疗法”起，经数十年临床应用与研究，已构建形成完善的理</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >、</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >法、方、药体系，研制消癖系列口服液，详见第三章。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >对于痰瘀互结及冲任失调型、同时具备多项乳腺癌发病高危因素的患者，因其有可能进一步发展至非典型性增生及乳腺癌的风险，应给予积极治疗。林毅教授针对痰瘀互结及冲任失调型乳腺增生病，在消癖系列口服液制剂基础上组方优化形成</font><font face="宋体" >“消癖颗粒”。方中以仙灵脾、肉苁蓉、郁金、丹参等药，发挥补肾助阳、疏肝活血、调摄冲任的功效。开展了“消癖颗粒”治疗乳腺增生病临床研究，以及预防乳腺癌发生发展、抑制乳腺癌转移、协同乳腺癌化疗增敏的系列基础研究。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(一)临床研究</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >为探讨消癖颗粒治疗乳腺增生病痰瘀互结、冲任失调型的有效性和安全性，研究团队设计了一项前瞻性、随机对照、双盲双模拟、多中心临床试验研究。研究纳入来自江苏省中医院、长春市中医院、北京中医药大学东方医院、湖南中医药大学第一附属医院、黑龙江中药大学附属第一医院、山东中医药大学附属医院、上海中医药大学附属曙光医院、首都医科大学附属北京中医医院和天津中医药大学第一附属</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >医院</font>8<font face="宋体" >家单位的</font><font face="Times New Roman" >478</font><font face="宋体" >例乳腺增生病痰瘀互结、冲任失调型患者。试验组</font><font face="Times New Roman" >359</font><font face="宋体" >例服用消癖颗粒和乳核散结片模拟剂，对照组</font><font face="Times New Roman" >119</font><font face="宋体" >例服用乳核散结片和消癖颗粒模拟剂。</font><font face="Times New Roman" >1</font><font face="宋体" >个月经周期为</font><font face="Times New Roman" >1</font><font face="宋体" >个疗程，连续观察时间为</font><font face="Times New Roman" >3</font><font face="宋体" >个月经周期，临床痊愈者随访</font><font face="Times New Roman" >1</font><font face="宋体" >个月，结果显示消癖颗粒对乳腺增生病的治疗作用整体明显优于乳核散结片。在</font><font face="Times New Roman" >95%CI</font><font face="宋体" >检验中，本品的疾病疗效和中医证候疗效总有效率最小值均大于优效性检验界值</font><font face="Times New Roman" >10%</font><font face="宋体" >。在治疗</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳房疼痛、触痛、乳腺质地、中医证候疗效等方面，消癖颗粒优势明显，且具有良好安全性。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(二)基础研究</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒成分复杂，其对乳腺癌的预防或抑制作用及其调控免疫信号的关键机制需要阐明，围绕精准辨证、生物学机制、活性物质基础和临床转化等方面开展全方位研究，不仅能丰富肿瘤免疫微环境信号的科学内涵，为有效干预肿瘤耐药和转移提供新机制、新靶点和新药物，也将阐释中西医结合防治乳腺癌的合理性和优势。在中医理论指导下，王志宇教授带领团队开展</font><font face="宋体" >“消癖颗粒”干预乳腺癌的现代医学机制探讨的系统研究，在此将近年来主要研究发现总结如下，希望能为广大中医药同道提供一定的参考，共同将中医药精华与现代多学科先进技术充分融合，积极协同创新，为我国中医药事业进一步走向现代化、国际化作出更大的贡献。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.1000pt;mso-char-indent-count:2.0000;line-height:150%;" ><b><span style="mso-spacerun:'yes';font-family:楷体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-weight:bold;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >1.消癖颗粒预防乳腺癌发生发展的作用及分子机制</span></b><b><span style="mso-spacerun:'yes';font-family:楷体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-weight:bold;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><o:p></o:p></span></b></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺癌是威胁女性健康和生命的最常见和高发恶性肿瘤。目前全世界每年约</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >有</font>140<font face="宋体" >万乳腺癌</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >新发患者，死亡率接近</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >14.1/100000</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。我国乳腺癌发病率亦居女性易患肿瘤第一位，并以每年</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >2%</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:华文仿宋;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >~</span><span style="mso-spacerun:'yes';font-family:华文仿宋;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >3%</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的增长速率递增，同时发病年龄趋于年轻化，正日益成为我国女性健康的主要杀手。如何安全有效地预防乳腺癌发生已成为降低患癌风险，提高生活质量及改善预后的关键环节</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >随着基因组学、蛋白质组学及细胞分子生物学的发展，已鉴定出众多高</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >风险因素与乳腺癌发生相关，如内分泌紊乱失调、易感基因</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >BRCAI/2</span></i><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >突变</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >、</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >肥胖等。近十年来肿瘤干细胞</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(cancer stem cells,</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CSCs)</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >相继在乳腺癌、淋巴瘤、肝癌、食道癌等肿瘤中发现，这类细胞具有自我更新、多向分化、强大的体内致瘤性和高度耐药及转移潜能，被认为是肿瘤发生和发展转移的根源。分子生物学研究表明肿瘤干细胞具有自我更新及不对称分裂等干细胞普遍特性，并具有强大的成瘤能力，在介导肿瘤发生、血管形成及复发转移等过程中发挥重要作用，以肿瘤干细胞关键调控信号为靶点的治疗策略成为预防肿瘤发生、控制肿瘤生</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >长及抑制复发转移的新策略。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >自</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >20世纪80年代鉴定出</span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >Wnt1</span></i><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >是乳腺肿瘤的原癌基因以来，</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Wnt/β-catenin</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >信号通路在乳腺癌预防和治疗过程中的作用日渐受到重视。正常干细胞中</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Wnt</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >信号介导的</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >β-catenin</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >表达由于受到泛素化蛋白酶体降解途径的调控而维持在正常水平。然而肿瘤干细胞中，由于蛋白降解复合体功能障碍及</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Wnt</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >信号的持续激活，</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >β-catenin</font><font face="宋体" >降解减少而</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >入</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >核增加，激活下游基因如</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >c-Myc</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >、</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >cyclin D1</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >和</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >CD44</span></i><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等，最终维持干细胞的自我更新和多向分化，同时越来越多的研究表明靶向</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Wnt/β-catenin</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >信号通路有可能成为预</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >防肿瘤发生的新途径。然而肿瘤的发生、发展不仅取决于肿瘤细胞本身，还取决于肿瘤细胞赖以生存的土壤，即肿瘤微环境。免疫细胞及其分泌的细胞因子是构成肿瘤微环境的重要组成部分。细胞毒性</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >T</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞、调节性</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >T</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞、肿瘤相关巨细胞</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(Tumor associated macrophages,TAMs)</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >及</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >TGF-β<font face="宋体" >、</font><font face="Times New Roman" >IFN-&#947;</font><font face="宋体" >、</font><font face="Times New Roman" >IL-6</font><font face="宋体" >、</font><font face="Times New Roman" >IL-12</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等细胞因子已被证明与肿瘤血管生成、复发转移及临床预后显著相关，由此而发展出的肿瘤免疫治疗也成为继手术、化疗、放疗之后的第</font>4类具有显著临床疗效及优势的抗肿瘤治疗方法。尽管</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Wnt/β-catenin,</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Notch<font face="宋体" >及</font><font face="Times New Roman" >Hedgehog</font><font face="宋体" >等内源性信号通路已被证明与</font><font face="Times New Roman" >CSCs</font><font face="宋体" >的自我更新及多向分化能力密切相关，但以其为靶点的治疗方式也不可避免地影响到正常干细胞的功能活动，从免疫微环境角度鉴定影响</font><font face="Times New Roman" >CSCs</font><font face="宋体" >的外源性信号通路不仅能丰富肿瘤干细胞的调控网络，也有可能为其靶向治疗提供新工具。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >最近的研究表明，调</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >节性</font>T<font face="宋体" >细胞</font><font face="Times New Roman" >Treg</font><font face="宋体" >可通过表达</font><font face="Times New Roman" >VEGF-A</font><font face="宋体" >、</font><font face="Times New Roman" >TGF-β</font><font face="宋体" >及</font><font face="Times New Roman" >IL-17</font><font face="宋体" >等细胞因子维持</font><font face="Times New Roman" >CSCs</font><font face="宋体" >群落数量及促进血管新生或上皮间质化过程</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >M2<font face="宋体" >型</font><font face="Times New Roman" >TAMs</font><font face="宋体" >也可通过分泌</font><font face="Times New Roman" >MFG-E8</font><font face="宋体" >促进</font><font face="Times New Roman" >CSCs</font><font face="宋体" >的体内成瘤能力及耐药特性。此外，多种细胞因子如</font><font face="Times New Roman" >IL-6</font><font face="宋体" >、</font><font face="Times New Roman" >IL-8</font><font face="宋体" >、</font><font face="Times New Roman" >CXCL7</font><font face="宋体" >也可通过与</font><font face="Times New Roman" >CSCs</font><font face="宋体" >表面受体</font><font face="Times New Roman" >CXCR1</font><font face="宋体" >或</font><font face="Times New Roman" >CXCR2</font><font face="宋体" >结合激活</font><font face="Times New Roman" >STAT3/NF-</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >&#954;B</font><font face="宋体" >通路促进其自我更新能力。由此免疫细胞及因子已成为调控</font><font face="Times New Roman" >CSCs</font><font face="宋体" >功能的重要靶标，基于免疫微环境因素抑制肿瘤干细胞自我更新及分化将成为肿瘤预防的有力武器</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >中医药是我国肿瘤治疗的特色，对患者机体的免疫调节更是中医药治疗肿瘤的独特优势。近十年来，大量实验证明多种抗肿瘤中药复方均可从调整</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >T</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞免疫功能、激活单核巨噬细胞和自然杀伤细胞、提高树突状细胞抗原提呈能力及逆转免疫逃逸等多方面增强患者的免疫功能，具有多环节、多靶点和整体调节的特点。然而由于化学成分复杂，大部分中药复方面临分子机制不清、物质基础不明等关键问题，导致科学转化困难重重，无法进行国际推广。现代医学认为乳腺癌发生经历了由</font><font face="宋体" >“正常</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >—</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >增生</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >—</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >非典型增生</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >—</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >原位癌</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >—</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >浸润性癌</font><font face="宋体" >”发展变化的多阶段发展模式，并且认为“正常</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >—增生—</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >非典型增生</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >—</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >原位癌</font><font face="宋体" >”属于可逆阶段，这为人们采取措施阻断癌前病变，降低乳腺癌发病率提供了理论基础。但是目前西医对乳腺癌前病变除手术切除外尚无有效治疗方法，同时激素疗法副作用大，仅对受体阳性患者有一定疗效，并可导致患者内分泌功能进一步紊乱，难以作为常规用药。中医学体系中乳腺癌属“乳岩”“乳石痈”“妒乳”等范畴。古代医家认为其发生主要是由于正气内虚、肝肾不足、冲任失调，加之七情所伤，脏腑失和，六淫邪毒乘隙内侵，内外合邪，致使经络受阻，气滞血瘀、痰凝毒聚而形成，肾虚血瘀为乳腺癌发病之本，所以补肾活血、调节免</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >疫、理气散结是预防乳腺癌发生的有效手段。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒方是林毅教授依据肾虚血瘀为乳腺癌前疾病的主要病机而确立的经验方，选定具有补肾助阳、疏肝活血、调摄冲任功效的药物仙灵脾、肉苁蓉、郁金、丹参、莪术、益母草、女贞子、制何首乌、鳖甲、牡蛎组成中药复方。方中以仙灵脾、肉苁蓉补肾助阳；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >郁金为血中气药，有疏肝活血</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >、</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >散结止痛之功</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >三药共为君药，以补肾助阳、疏肝活血、调摄冲任而治本</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >丹参、莪术、益母草疏肝活血，且能养血调经止痛，气血通畅则冲任自调并增强君药补肾活血、调摄冲任之功，共为臣药</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >佐以女贞子、制何首乌</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >、</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >鳖甲以养血滋阴润燥</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >鳖甲辅以牡蛎软坚散结以治标。且君药其性属</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >阳，佐药其性属阴，阳得阴助则生化无穷，并防肝郁化火、耗劫阴津之弊。诸药合用，标本兼治，共奏补肾助阳、疏肝活血、调摄冲任之功。临床前药效学研究发现，消癖颗粒能有效改善血液流变性，降低乳腺增生的乳腺小叶数、腺泡数、腺泡腔直径及胞浆面积，同时可显著阻断化学致癌剂</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >DMBA<font face="宋体" >诱导的乳腺癌前病变。急性毒性和长期毒性试验亦表明，消癖颗粒在推荐</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的成人临床用药剂量是安全的。临床</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >&#8544;</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >期和</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >&#8545;</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >期试验表明消癖颗粒前身</font><font face="宋体" >“消癖系列口</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >服液</font><font face="宋体" >”能有效缩小乳腺增生肿块、降低肿块密度、改善乳腺增生病的不良结构、缓解疼痛及减轻伴随症状，疗效优于三苯氧胺阳性对照组，且无毒副作用。以上数据表明消癖颗粒有可能作为一级或二级预防手段干预乳腺癌前疾病，降低乳腺癌发生风险。然而其对免疫功能的调节和乳腺癌干细胞的作用尚不清楚，物质基础也需要进一步明确，应用现代多学科交叉技术阐明其分子机制和药效物质基础，是促进消癖颗粒科学化、标准化融入世界医学体系的必需步骤。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >此部分研究中，我们首先采用乳腺癌自发转基因小鼠模型</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MMTV-PyVT+/-</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >证明消癖颗粒给药后乳腺癌发生数目、发生时间、肿瘤体积均显著减小或延迟，同时消癖颗粒对小鼠体重无显著影响，乳腺组织胭脂红染色证明消癖颗粒给药后可显著延迟乳腺原位癌生长，减缓肿瘤发生时间。为检测消癖颗粒对体外乳腺癌细胞生长抑制作用，我们</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >采用</font>MTT<font face="宋体" >法检测消癖颗粒对人雌激素受体阳性乳腺癌细胞系</font><font face="Times New Roman" >MCF-7</font><font face="宋体" >、三阴性乳腺癌细胞系</font><font face="Times New Roman" >MDA-MB-231,</font><font face="宋体" >以及人乳腺正常上皮细胞</font><font face="Times New Roman" >MCF-10A</font><font face="宋体" >的生长抑制作用。结果表明消癖颗粒对</font><font face="Times New Roman" >MCF-7</font><font face="宋体" >生长无显著抑制作用，而对三阴性乳腺癌细胞仅在大于</font><font face="Times New Roman" >800&#181;g/mL</font><font face="宋体" >的浓度时有抑制作用，同时对乳腺正常细胞</font><font face="Times New Roman" >MCF-10A</font><font face="宋体" >无显著抑制作用，提示消癖颗粒在体外对乳腺癌细胞生长抑制作用微弱，同时无显著细胞毒性作用。细胞恶性转化实验亦证实消癖颗粒对原癌基因</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >Ras</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >转化的</font>MCF-10A<font face="宋体" >细胞系克隆生长无显著抑制作用，提示消癖颗粒并不能直接抑制细胞恶性转化。同时乳腺癌干细胞群落分析实验也证明消癖颗粒在体外对乳腺癌干细胞的自我更新无显著抑制作用</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，提示消癖颗粒的乳腺癌体内预防作用的分子机制可能与肿瘤微环境调控相关。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在此基础上，我们利用在线中药数据库</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >TCMID<font face="宋体" >、</font><font face="Times New Roman" >TCMSP</font><font face="宋体" >、</font><font face="Times New Roman" >BATMAN</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >及《中药大辞典》</font>(第二版)查找消癖颗粒中所含10种中药的化学成分及对应靶点。运用</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >ADME<font face="宋体" >预测进行首轮化合物筛选</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >：</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >ADME</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >absorption<font face="宋体" >吸收、</font><font face="Times New Roman" >distribution</font><font face="宋体" >分布、</font><font face="Times New Roman" >metabolism</font><font face="宋体" >代谢、</font><font face="Times New Roman" >excretion</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >排泄</font>)是衡量化合物成药性的关键指标。筛选条件为</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >：入</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >选化学成分的类药性</font>(</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >drug-like,</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >DL</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >)</span><span style="mso-spacerun:'yes';font-family:新宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="新宋体" >≥</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >0.18</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，有助于优化药代动力学和药物性能，如溶解度和化学稳定性的估计</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >口服生物利用度</font>(</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >oral bioavailability,</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;<font face="Times New Roman" >O</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >B</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >)</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&gt;30%</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。结果显示消癖颗粒生物活性</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >成分</font>105<font face="宋体" >个，潜在靶点</font><font face="Times New Roman" >806</font><font face="宋体" >个。其中</font><font face="Times New Roman" >9</font><font face="宋体" >种中药共有</font><font face="Times New Roman" >2</font><font face="宋体" >个靶点，</font><font face="Times New Roman" >8</font><font face="宋体" >种中药共有</font><font face="Times New Roman" >9</font><font face="宋体" >个靶点，</font><font face="Times New Roman" >7</font><font face="宋体" >种中药共有</font><font face="Times New Roman" >23</font><font face="宋体" >个靶点，</font><font face="Times New Roman" >6</font><font face="宋体" >种中药共有</font><font face="Times New Roman" >30</font><font face="宋体" >个靶点，</font><font face="Times New Roman" >5</font><font face="宋体" >种中药共有</font><font face="Times New Roman" >65</font><font face="宋体" >个靶点，</font><font face="Times New Roman" >4</font><font face="宋体" >种中药共有</font><font face="Times New Roman" >69</font><font face="宋体" >个靶点。与乳腺癌靶点数据库</font><font face="Times New Roman" >GENECARDS</font><font face="宋体" >和</font><font face="Times New Roman" >GSE5764</font><font face="宋体" >基因芯片杂交后，共筛选出</font><font face="Times New Roman" >81</font><font face="宋体" >个基因可能参与消癖颗粒抗乳腺癌的作用。基因功能富集分析显示</font><font face="Times New Roman" >81</font><font face="宋体" >个基</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >因主要和肿瘤微环境调控密切相关</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >为证实消癖颗粒对乳腺癌生长微环境的作用和机制，我们随后采用流式分选技术从小鼠乳腺实体肿</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >瘤中以</font>CD11b<font face="宋体" >和</font><font face="Times New Roman" >CD206</font><font face="宋体" >为标记分选出肿瘤相关巨噬细胞</font><font face="Times New Roman" >TAMs</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >tumor-associated macrophages</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >)，于体外传代培养。其次采用细胞因子芯片法分别研究消癖颗粒施加后对小鼠体内血浆中细胞因子和</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >体外</font>TAMs<font face="宋体" >培</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >养上清中细胞因子的影响，综合体内外研究结果，消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >对</font>4<font face="宋体" >种细</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >胞因子</font>(</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >G-CSF<font face="宋体" >、</font><font face="Times New Roman" >CCL2</font><font face="宋体" >、</font><font face="Times New Roman" >CXCL2</font><font face="宋体" >、</font><font face="Times New Roman" >CXCL1</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >)的抑制作用在体内外具</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >有一致性，因为这</font>4<font face="宋体" >种细胞因子均与</font><font face="Times New Roman" >TAMs</font><font face="宋体" >紧密相关，我们采用免疫荧光法检测消癖颗粒对</font><font face="Times New Roman" >TAMs</font><font face="宋体" >的影响，结果提示</font><font face="Times New Roman" >CD11b/CD206</font><font face="宋体" >标记的</font><font face="Times New Roman" >TAMS</font><font face="宋体" >在消癖颗粒治疗组显著减少，同时</font><font face="Times New Roman" >qPCR</font><font face="宋体" >结果也证实在消癖颗粒治疗组肿瘤组织中</font><font face="Times New Roman" >CXCL-1</font><font face="宋体" >抑制作用最显著。</font><font face="Times New Roman" >Elisa</font><font face="宋体" >和免疫蛋白印迹实验均证实消癖颗粒可剂量依赖性降低巨细胞分泌和表达的</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >因子水平，定量</font><font face="Times New Roman" >PCR</font><font face="宋体" >再次验证了消癖颗粒作用后巨噬细胞中</font><font face="Times New Roman" >CXCL1mRNA</font><font face="宋体" >表达水平下降，同时荧光报告基因结果也证明消癖颗粒对</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >的转录活性具有直接抑制作用，以上结果提示消癖颗粒可能通过</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >的调控降低乳腺癌干细胞数量，从而实现乳腺癌的预防作用。</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺癌干细胞是肿瘤发生的根源。为了探讨消癖颗粒对共培养体系中乳腺癌干细胞的调控作用，我们首先采用</font>ALDH<font face="宋体" >法检测消癖颗粒施加后干细胞群落比例的变化。研究结果显示随消癖颗粒浓度升高，</font><font face="Times New Roman" >ALDH+</font><font face="宋体" >细胞在乳腺癌细胞中的比例呈剂量依赖性下降，同时成球能力也显示干细胞的成球数量显著缩小，说明消癖颗粒能够通过对</font><font face="Times New Roman" >TAMs</font><font face="宋体" >的调控抑制乳腺癌干细胞自我更新的能力。定量</font><font face="Times New Roman" >PCR</font><font face="宋体" >研究结果显示消癖颗粒作</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >用后</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >β-calenin</font></span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >,</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >OCT4</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >和</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >Nanog</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的</font>mRNA<font face="宋体" >水平在乳腺癌细胞中均呈剂量依赖性降低，由于</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >β-catenin</font></span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >是</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >OCT4</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >和</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >Nanog</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的上游基因</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >所以后续我们进行了免疫蛋白印迹的验证。研究结果证明消癖颗粒可剂量依赖性降低</font>2<font face="宋体" >种乳腺癌细胞中</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >β-catenin</font></span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的表达水平。由于</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >β-catenin</font></span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >是控制乳腺癌干细胞自我更新的关键基因，从而说明消癖颗粒可能通过调控</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >β-catenin</font></span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >通路抑制乳腺癌干细胞的活性。为了探讨消癖颗粒是否通过</font>CXCL1<font face="宋体" >调控乳腺癌干细胞中</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >β-catenin</font></span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >通路，我们再次检测了</font>CXCL1<font face="宋体" >施加后对乳腺癌细胞中干细胞群落比例和成球能力的影响，研究表明随</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >浓度增加，乳腺癌细胞中干细胞比例逐渐上升，成球能力显著增强，而</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >可显著削弱消癖颗粒所诱导的细胞抑制作用，说明</font><font face="Times New Roman" >TAMS/CXCL1</font><font face="宋体" >是消癖颗粒抑制乳腺癌干细胞活性的重要靶点。定量</font><font face="Times New Roman" >PCR</font><font face="宋体" >和免疫蛋白印迹的结果也证实</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >可显著削弱消癖颗粒对干细胞通路关键分子</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >β-catenin</font></span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >,</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >OCT4</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >和</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >Nanog</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的抑制作用，证明</font>TAMs/CXCL1/β-catenin<font face="宋体" >通路是消癖颗粒抑制乳腺癌干细胞活性的重要分子机制。</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >综上所述，此部分研究我们从免疫微环境的角度揭示了中药复方消癖颗粒预防乳腺癌的作用和分子机制，为其临床应用提供了科学依据，有可能发展成为乳腺癌高风险人群患者的一级预防和二级预防的新手段，促进了中医药的科学转化，为乳腺癌有效预防及调控肿瘤干细胞寻找到新的分子靶点，同时为乳腺癌预防药物开发提供了新的思路。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.1000pt;mso-char-indent-count:2.0000;line-height:150%;" ><b><span style="mso-spacerun:'yes';font-family:楷体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-weight:bold;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >2.消癖颗粒抑制乳腺癌转移的作用及分子机制</span></b><b><span style="mso-spacerun:'yes';font-family:楷体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-weight:bold;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><o:p></o:p></span></b></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >转移</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >复发是导致肿瘤临床治疗失败及多数癌症患者死亡的主要原因。乳腺癌高居全球女性易发肿瘤第一位，尽管其诊疗手段近年来不断完善，但死亡率仍得不到有效控制。</font>90%<font face="宋体" >以上的乳腺癌患者死亡是由肿瘤转移造成的</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >转移部位多见肺、骨、脑。同时约</font>6%<font face="宋体" >的患者最初被诊断为转移性乳腺癌</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >20%</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >~</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >50%<font face="宋体" >的原发性乳腺癌患者在首次确诊后</font><font face="Times New Roman" >3</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >~</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >10<font face="宋体" >年或更长时间会发生远处转移，部分患者肿瘤发生早期在血液和骨髓中即可检测到循环癌细胞的存在</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >因此探索乳腺癌转移机制及发展治疗靶标是提高疗效、改善预后及延长生存期的关键环</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >节。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >肿瘤侵袭转移研究目前多聚焦于肿瘤细胞本身恶性生物学行为的调控解析，如上皮间质转化、血管新生、细胞外基质降</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >解、细胞骨架重构、代谢重编程等通路。在此过程中，鉴定出众多与肿瘤恶性侵袭密切相关的基因，包括</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >MTS</span></i><i><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-style:italic;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >1</font></span></i><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >、</font>BMI1<font face="宋体" >、</font><font face="Times New Roman" >VEGF</font><font face="宋体" >、</font><font face="Times New Roman" >CTNNB</font></span></i><i><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-style:italic;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >1</font></span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等，然而迄今为止没有一个真正的抗肿瘤转移靶向药物上市，其原因不仅与肿瘤转移是一个多基因、多因素、多步骤参与的复杂调控过程有关，而且与转移靶器官的微环境重塑密切相连。早在</font>1889<font face="宋体" >年，</font><font face="Times New Roman" >Paget</font><font face="宋体" >在对晚期乳腺癌转移的观察中就提出了</font><font face="Times New Roman" >“</font><font face="宋体" >种子与土壤</font><font face="Times New Roman" >”</font><font face="宋体" >假说，认为作为</font><font face="Times New Roman" >“</font><font face="宋体" >种子</font><font face="Times New Roman" >”</font><font face="宋体" >的肿瘤细胞可以随循环到达全身，但只能在特定的靶器官土壤中生存并生长，最终形成转移灶。</font><font face="Times New Roman" >Kaplan</font><font face="宋体" >等</font><font face="Times New Roman" >2017</font><font face="宋体" >年进一步证实原位肿瘤分泌组分对诱导远端位点形成新转移灶具有重要作用，其发现乳腺癌细胞培养上清中</font><font face="Times New Roman" >FLT3</font><font face="宋体" >蛋白配体不仅可以特异性扩增</font><font face="Times New Roman" >Sca-1+/c-Kit+HSPC</font><font face="宋体" >，而且可以吸引</font><font face="Times New Roman" >HSPC</font><font face="宋体" >向肺组织趋向运动分化为</font><font face="Times New Roman" >CD11b+Gr-1+</font><font face="宋体" >源性抑制细</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >胞</font>(</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >myeloid-derived suppressor cells,</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MDSCs</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >)构建免疫抑制微环境，最终促进远端转移灶形成。乳腺癌细胞在缺氧条件下诱导表达的单核细胞趋化因子(</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >monocytechemotactie protein-1,MCP-1</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >)、碳酸酐酶</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >&#8552;</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;carbonic anhydrase &#8552;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CA&#8552;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >)赖氨酰氧化酶(</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >lysyloxidase,LOX</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >)同样被发</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >现能趋向诱导</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MDSCs<font face="宋体" >在肺</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >部形</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >成多形核白细胞</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >polymorphonuclear lenkocyte,PMN</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >)并抑制免疫细胞杀伤功能。另一项乳腺癌研</span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >究也发现</font>I<font face="宋体" >型干扰素敲除可以通过升高髓源性中性粒细胞</font><font face="Times New Roman" >CXCR2</font><font face="宋体" >表达并诱导其向肺部趋向运动，减弱其细胞杀伤能力，同时增强</font><font face="Times New Roman" >PMN</font><font face="宋体" >中标志性促转移蛋白</font><font face="Times New Roman" >S100A8</font><font face="宋体" >、</font><font face="Times New Roman" >S100A9</font><font face="宋体" >、</font><font face="Times New Roman" >Fibronectin(Fn)</font><font face="宋体" >和</font><font face="Times New Roman" >MMP-9</font><font face="宋体" >的</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >表达，从而导致肺部转移灶形成。此外，近年来外泌体在介导转移形成过程中的重要作用日益受到</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >关注。</font>Lyden<font face="宋体" >等研究发现胰腺导管癌细胞分泌的外泌体可通过释放巨噬细胞迁移抑制因子</font><font face="Times New Roman" >(macrophage migration inhibitory factor,MIF)</font><font face="宋体" >被肝脏</font><font face="Times New Roman" >Kupfer</font><font face="宋体" >细胞吞噬，增强</font><font face="Times New Roman" >TGF-β</font><font face="宋体" >激活肝卫星细胞表达</font><font face="Times New Roman" >FN</font><font face="宋体" >，继而吸引髓源性巨噬细胞迁移至肝脏促进转移灶形成。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >综上所述</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，肿瘤转移的形成主要包括三个有序进行的阶段</font>:<font face="宋体" >在准备阶段，原位肿瘤分泌各种可溶性因子、细胞外囊泡或外泌体，在预转移组织位点形成一个非成熟的诱导微环境</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在许可阶段，</font>HSPC<font face="宋体" >及免疫抑制性细胞被动员激活并向预转移组织位点趋向募集，一方面抑制预转移灶免疫杀伤能力，另一方面与此处基质细胞共同作用，增加促转移标志物</font><font face="Times New Roman" >S100A8</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >、</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >S100A9<font face="宋体" >、</font><font face="Times New Roman" >FN</font><font face="宋体" >和</font><font face="Times New Roman" >MMP-9</font><font face="宋体" >的表达</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在形成阶段，循环肿瘤细胞达到并定植于靶器官形成微小转移灶，并进一步促进转移微环境成熟以吸引更多</font>HSPCs<font face="宋体" >和肿瘤细胞趋向转移，最终形成临床可见的转移灶。由此可见靶向免疫抑制微环境已成为预防肿瘤转移、改善预后的有力武器，然而免疫抑制微环境形成过程中各种细胞与因子</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >之间调控网络结构极其复杂，仍存在大量未明确的可能机制，探寻新的诱导因子及靶标细胞是未来的重要研究热点。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >中医药对肿瘤转移具有独到的见解。《黄帝内经》将转移称为</font><font face="宋体" >“传舍</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >”</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >,包括三要素：</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >①癌毒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >②正虚</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >③气滞、血瘀、痰凝，形象地描述了对转移前微环境的认识。肿瘤之所以转移，一是癌症的邪气盛，二是被转移的部位正气虚，形成瘀滞的土壤和环境，所谓“邪之所凑，其气必虚”，故而正气强弱是决定肿瘤转移的重要因素，正气盛衰也决定肿瘤转移方式和速度，所以肿瘤巩固治疗期间的指导原则是“先安未受邪之地”，提高整体未侵犯部位的正气，改善转移前微环境，消除肿瘤的转移基础，从而起到预防转移的作用。根据“治未病”思想，预先治疗未病的脏腑，调畅转移前</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >脏器整体和局部气机、改善转移前微环境，使癌毒不能侵入是中医药防治转移的主要策略。中医对恶性肿瘤转移的认识最早可追溯到秦汉时期。《灵枢</font><font face="宋体" >&#183;百病始生》指出</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >:“是故虚邪之中人也，始于皮肤……</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >留而不去，传舍于伏冲之脉</font><font face="宋体" >……</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >留而不去，传舍于胃肠之外，募原之间。留著于脉，稽留而不去</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，息而成积</font><font face="宋体" >”，可以在通俗意义上理解为古人对于转移性肿瘤的朴素认识，指出正虚是“传舍”发生、发展的原因，而经络系统是病邪转移的途径。后世医家继承了这种观点，认为肿瘤是一种全身属虚，局部属实的病证。恶性肿瘤自始至终表现出正气为癌毒耗散的证候，特别是晚期已发生转移者，癌毒稽留而不去，加之攻伐太过，导致正气抗击病毒的能力下降，则可能发生扩散，传舍至机体某一局部则成为新的病灶。“最虚之处，便是客邪之地”，机体某一局部的“最虚”，亦是形成转移前微环境的必要条件。从这些论述可以看出，癌毒内生、正虚失固是癌症发生、发展的根本原因，加之气滞、痰凝、血瘀，进一步促进转移的形成。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >癌毒是恶性肿瘤发生、发展的直接病因，也是造成癌瘤转移的内在根本因素。癌毒概念的提出源自中医的毒邪理论，如《金匮要略心典》认为：</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >“毒者，邪气蕴结不解之谓。”癌毒特性的两大关键:一是易于扩散，发生传舍</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >一是易于耗散正气，导致正虚不固。一般情况下，癌毒炽盛，发生转移的可能性越大，发生转移的时间也越早。恶性肿瘤的初期阶段，主要表现为癌毒在原发灶周围的积聚和侵袭</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >：</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >中期阶段，癌毒可沿络脉、经脉流散，在适宜的环境下形成转移病灶</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >随着癌毒淫溢，正气固摄能力愈弱，癌毒的传舍趋势愈盛，毒炽正虚形成恶性循环，恶性肿瘤逐渐进入晚期</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。由此可见，癌毒炽盛是形成转移的先决条件。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >随着癌毒不断地积聚侵袭，正虚证候不断加重，局部脏器出现气滞、血瘀、痰凝的辨证特点，形成</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >塑造</font>PMN<font face="宋体" >的辅助</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >因素。临床肿瘤患者均不同程度地伴有气滞、血瘀和痰凝证候。现代医学认为血液高凝状态为游离的癌细胞在小血管中着床侵入其他组织形成转移创造了条件，而血液的高粘状态与中医血瘀证密切相关。基础研究发现痰与黏附分子性质颇多类似，化痰药可以影响癌细胞表面黏附分子的表达，从而减少肿瘤的生长和侵袭转移。由此可见气滞、血瘀、痰凝为肿瘤细胞着床创造了便利条件，是促进转移形成的有利土壤。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >综上所述，肿瘤转移形成过程可归纳如下：</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >癌毒的积聚生长是造成转移的先决因素。全身及局部的阴阳气血之虚是癌毒扩散的必要条件。气滞、痰凝、血瘀是转移形成的重要辅助。此外，《灵枢</font><font face="宋体" >&#183;百病始生》提示</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >：</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >“其中于虚邪也，因于天时，与其身形，参以虚实，大病乃成”，所以肿瘤转移的形成还与环境气候因素及个体的体质因素等有关。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >中医药防治肿瘤的优势在于治未病，有效预防复发转移，延长患者的生存时间，其认识源于《黄帝内经》：</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >“不治已病治未病”，主要包括未病先防、已病早治、既病防变，强调防治疾病时要有整体观念，预先治疗未病的脏腑，所谓“见肝之病，知肝传脾，当先实脾”，其宗旨就是按照“先其所因”的原则，调畅转移前脏器局部气机、改善转移前微环境，使癌毒不能侵</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >入</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，从而起到抗肿瘤转移的作用。大量临床及基础研究表明中医药起效的根本机制在于整体调控宿主</font>-肿瘤微环境，尤其是对肿瘤微环境中非癌成分的调控，同时由于肿瘤复杂的分子网络，针对单一的靶点治疗并不能起到预期的效果，这也正是中医发挥自身优势的机遇。近十年来，</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >诸多临床及实验研究证明多种抗肿瘤中药复方均可从调整</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >T</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞免疫功能、激活单核巨细胞和自然杀伤细胞、提高树突状细胞抗原提呈能力及逆转免疫逃逸等多方面增强患者的免疫功能，从而达到抑制和预防肿瘤转移的目的，而且具有多环节、多靶点和整体调节的特点。有研究证实当归补血汤改良方</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >KSG-002<font face="宋体" >可以通过靶向微环境中巨噬细胞分泌</font><font face="Times New Roman" >TNFα</font><font face="宋体" >抑制乳腺癌生长和转移，健脾补肾方可以降低胃癌模型肺预转移灶中纤黏蛋白的表达水平，通过对转移免疫微环境的调控设计阻断肿瘤转移的干预策略，将会引起治疗模</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >式的变革</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >此部</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >分研究中，为了探讨消癖颗粒的抗转移作用及</font>TAMS/CXCL1<font face="宋体" >通路的关键地位，使用</font><font face="Times New Roman" >Balb/C</font><font face="宋体" >免疫功能健全的小鼠进行原位乳腺癌模型的建立。将荧光素酶基因转染的</font><font face="Times New Roman" >4T1-Luc</font><font face="宋体" >小鼠乳腺癌细胞接种到第四对乳腺脂肪垫，同时给予消癖颗粒治疗</font><font face="Times New Roman" >1g/(kg&#183;d)</font><font face="宋体" >，观察对照组和给药组乳腺肿瘤的生长情况。研究结果显示消癖颗粒可显著抑制小鼠乳腺癌原位生长体积及后期的肺转移的发生，而对体重无显著影响。通过提取小鼠乳腺肿瘤原代细胞，进行</font><font face="Times New Roman" >M2</font><font face="宋体" >型巨细胞群落比例的测定，研究结果显示消癖颗粒给药组小鼠肿瘤中</font><font face="Times New Roman" >TAMs</font><font face="宋体" >比例显著缩小，免疫荧光也显示消癖颗粒给药后，乳腺肿瘤中</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >蛋白表达显著减弱，证实了消癖颗粒在体内可显著抑制</font><font face="Times New Roman" >TAMS/CXCL1</font><font face="宋体" >通路。为了探讨</font><font face="Times New Roman" >TAMs</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >/</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CXCL1<font face="宋体" >信号在介导</font><font face="Times New Roman" >XPS</font><font face="宋体" >抑制乳腺癌转移过程中的重要作用，建立了</font><font face="Times New Roman" >TAMs</font><font face="宋体" >与乳腺癌细胞共注射模型。研究结果显示</font><font face="Times New Roman" >TAMs</font><font face="宋体" >可显著促进乳腺癌生长和转移，而</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >在</font><font face="Times New Roman" >TAMs</font><font face="宋体" >中的敲除可显著抑制乳腺癌生长和转移，消癖颗粒的抗肿瘤作用可被</font><font face="Times New Roman" >CXCL</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="Times New Roman" >1</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >基因在</font>TAMs<font face="宋体" >中的上调显著削弱。同时我们对肿瘤组织中</font><font face="Times New Roman" >TAMs</font><font face="宋体" >和髓源性抑制细胞</font><font face="Times New Roman" >MDSCs</font><font face="宋体" >的含量行流式分析检测，结果发现消颗粒可显著降低</font><font face="Times New Roman" >TAMs</font><font face="宋体" >和</font><font face="Times New Roman" >MDSCs</font><font face="宋体" >在肿瘤实质中的群落数量，而</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >在</font><font face="Times New Roman" >TAMs</font><font face="宋体" >中的上调可显著抑制消癖颗粒对</font><font face="Times New Roman" >TAMS</font><font face="宋体" >和</font><font face="Times New Roman" >MDSCs</font><font face="宋体" >的调控作用。以上结果提示消癖颗粒可通过调控</font><font face="Times New Roman" >TAMS/CXCL1</font><font face="宋体" >通路抑制乳腺癌体内生长和转移。</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >为了探讨</font>TAMS/CXCL1<font face="宋体" >促进乳腺癌细胞转移的分子机制，首先采用</font><font face="Times New Roman" >MTT</font><font face="宋体" >法证实</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >对人乳腺癌细胞</font><font face="Times New Roman" >MDA-MB-231</font><font face="宋体" >和鼠乳腺癌细胞系</font><font face="Times New Roman" >4T1</font><font face="宋体" >均没</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >有显著的增殖促进作用，然而划痕</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >实验和</font>Transwell<font face="宋体" >实验证实</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >可显著促进小鼠乳腺癌细胞</font><font face="Times New Roman" >4T1</font><font face="宋体" >迁移和侵袭，同时</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >可显著上调间质化蛋白</font><font face="Times New Roman" >vimentin</font><font face="宋体" >、</font><font face="Times New Roman" >β -catenin</font><font face="宋体" >和</font><font face="Times New Roman" >N-cadherin</font><font face="宋体" >表达含量，而降低上皮标志蛋白</font><font face="Times New Roman" >E-cadherin</font><font face="宋体" >的表达水平。随后我们采用</font><font face="Times New Roman" >IL-4</font><font face="宋体" >联合</font><font face="Times New Roman" >IL-13</font><font face="宋体" >诱导巨细胞</font><font face="Times New Roman" >Raw264.7</font><font face="宋体" >进行</font><font face="Times New Roman" >M2</font><font face="宋体" >转变，</font><font face="Times New Roman" >Elisa</font><font face="宋体" >法比较</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >在肿瘤细胞、巨细胞和肿瘤相关巨细胞里的表达水平，发现</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >在</font><font face="Times New Roman" >TAMs</font><font face="宋体" >中表达最高，并且</font><font face="Times New Roman" >TAMs</font><font face="宋体" >上清液的施加并不影响</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >在肿瘤细胞</font><font face="Times New Roman" >4T1</font><font face="宋体" >中的表达水平，说明</font><font face="Times New Roman" >TAMs</font><font face="宋体" >是</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >的主要来源。更为重要的是，在</font><font face="Times New Roman" >TAMs</font><font face="宋体" >上清液中加入</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >中和抗体后，发现</font><font face="Times New Roman" >TAMs</font><font face="宋体" >诱导的细胞迁移和侵袭能力被显著阻断，说明</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >在</font><font face="Times New Roman" >TAMS</font><font face="宋体" >诱导转移过程中发挥了重要作用。</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >分子机制层面，我们首先采用</font>qPCR<font face="宋体" >筛选法探讨了</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >对</font><font face="Times New Roman" >15</font><font face="宋体" >种转移相</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >关基因的作用，发</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >现</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >SOX4</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在乳腺癌细胞中是应答最高基因，免疫荧光法进一步发现</font>CXCL1<font face="宋体" >可促进</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >SOX4</span></i><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >入</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >核表达。同时我们外源性提高</font>CXCL1<font face="宋体" >表达后，</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >SOX4</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >和间质化蛋白表达水平均显著升高，而敲除</font>CXCL1<font face="宋体" >表达后，</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >SOX4</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >和间质化蛋白表达水平均显著降低。更为重要的是，</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >SOX4</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >沉默后，</font>CXCL1<font face="宋体" >介导的</font><font face="Times New Roman" >EMT</font><font face="宋体" >转变被显著阻断，说明</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >SOX4</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >是介导</font>CXCL1<font face="宋体" >促转移能力的重要因子。因为</font><font face="Times New Roman" >NF-&#954;B</font><font face="宋体" >是</font><font face="Times New Roman" >SOX4</font><font face="宋体" >的转录因子，所以我们继续研究了</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >对</font><font face="Times New Roman" >NF-&#954;B</font><font face="宋体" >通</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >路的激活作用</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。研究发</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >现</font>CXCL1<font face="宋体" >施加后，</font><font face="Times New Roman" >p-IKBα/IKBα</font><font face="宋体" >、</font><font face="Times New Roman" >p-P65/P65</font><font face="宋体" >、</font><font face="Times New Roman" >p-IKKαβ</font><font face="宋体" >、</font><font face="Times New Roman" >IKKα</font><font face="宋体" >、</font><font face="Times New Roman" >IKBKB</font><font face="宋体" >在乳腺癌细胞中均表达增加，提示</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >可激活</font><font face="Times New Roman" >NF-&#954;B</font><font face="宋体" >通路。另一方面，当在肿瘤巨噬细胞中敲低</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >表达，取其上清与乳腺癌细胞共培养后，发现</font><font face="Times New Roman" >p-P65/P65</font><font face="宋体" >的激活被显著阻断，同时</font><font face="Times New Roman" >NF-&#954;B</font><font face="宋体" >通路抑制剂</font><font face="Times New Roman" >Bay11-7082</font><font face="宋体" >施</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >加</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >后，</font>CXCL1<font face="宋体" >诱导的</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >SOX4</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >和</font>EMT<font face="宋体" >增强作用均被阻断。我们继续构建了</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >SOX4</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >荧光报告基因质粒，将其转染至</font>MDA-MB-231<font face="宋体" >和</font><font face="Times New Roman" >MCF-7</font><font face="宋体" >细胞，发现</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >可剂量依赖性增加</font><font face="Times New Roman" >SOX4</font><font face="宋体" >的基因转录，而同时加入</font><font face="Times New Roman" >NF-&#954;B</font><font face="宋体" >抑制剂后，可显著抑制</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >引起的</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >SOX4</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >转录活性增高。为了进一步探讨</font>CXCL1<font face="宋体" >能否增加</font><font face="Times New Roman" >NF-&#954;B</font><font face="宋体" >与</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >SOX4</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >基因启动子区的结合，我们使用</font>JSAPAR<font face="宋体" >软件预测了</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >SOX4</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >基因启动子区域</font>NF-&#954;B<font face="宋体" >的结合位点，发现</font><font face="Times New Roman" >-806</font><font face="宋体" >到</font><font face="Times New Roman" >-817</font><font face="宋体" >区域为可能结合区域，随后使用基于</font><font face="Times New Roman" >NF-&#954;B</font><font face="宋体" >抗体的染色质免疫共沉淀技术扩增了此区域，发现</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >可显著促进</font><font face="Times New Roman" >NF-&#954;B</font><font face="宋体" >诱导的靶标基因片段扩增，而</font><font face="Times New Roman" >NF-&#954;B</font><font face="宋体" >抑制剂</font><font face="Times New Roman" >Bay11-7082</font><font face="宋体" >施加后可逆转此过程，充分说明</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >可通过促进</font><font face="Times New Roman" >NF-&#954;B</font><font face="宋体" >介导的</font></span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >SOX4</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >基因转录诱导乳腺癌细胞</font>EMT<font face="宋体" >的发生。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >同时</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >对</font>CXCL1<font face="宋体" >在乳腺癌临床预后中的意义进行了分析，首先使用</font><font face="Times New Roman" >TCGA</font><font face="宋体" >数据库分析了</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >在</font><font face="Times New Roman" >Metabric(n=2509)</font><font face="宋体" >和</font><font face="Times New Roman" >TCGA(n=825)</font><font face="宋体" >两个队列中的临床意义。</font><font face="Times New Roman" >cBioportal</font><font face="宋体" >分析表明</font><font face="Times New Roman" >CXLC1</font><font face="宋体" >在两个队列中高表达比例占</font><font face="Times New Roman" >4%~7%</font><font face="宋体" >，均在基底型乳腺癌中呈现高表达状态。同时我们从</font><font face="Times New Roman" >oncomine</font><font face="宋体" >数据库中提取了</font><font face="Times New Roman" >Sorlie</font><font face="宋体" >研究，结果发现</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >高表达与乳腺癌总生存时间</font><font face="Times New Roman" >(P=0.0186)</font><font face="宋体" >和无复发生存</font><font face="Times New Roman" >(P=0.0442)</font><font face="宋体" >均显著相关。同时</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >联合</font><font face="Times New Roman" >NF-</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >&#954;</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >B<font face="宋体" >具有更好的生存期预后意义，更为有趣的是，</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >在</font><font face="Times New Roman" >BRCA1/2</font><font face="宋体" >突变的乳腺癌患者中表达水平也显著升高。组织芯片研究发现</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >在乳腺癌组织中的表达显著高于正常组织，同时</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >与总生存时间显著相关</font><font face="Times New Roman" >(P&lt;0.001)</font><font face="宋体" >，同时其与</font><font face="Times New Roman" >TNM</font><font face="宋体" >分期、淋巴结转移和淋巴管浸润均显著相关，是影响生存期的独立风险因素。</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >综上所述，本研究为中医药整体观和</font><font face="宋体" >“邪之所凑，其气必虚”的重大理论研究提供了强力证明，体现了肿瘤转移过程中正与邪的辩证关系，突出了肿瘤转移是肿瘤局部与宿主整体之间相互作用的过程，体现了肿瘤间质细胞在介导肿瘤转移过程中的关键作用，为指导中医药临床实践提供了科学证据，促进了中医药理论的科学转化，同时也为转移早期干预和阻断提供了新的靶向策略和药物靶点</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.1000pt;mso-char-indent-count:2.0000;line-height:150%;" ><b><span style="mso-spacerun:'yes';font-family:楷体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-weight:bold;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >3.消癖颗粒协同乳腺癌化疗增敏的作用及分子机制</span></b><b><span style="mso-spacerun:'yes';font-family:楷体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-weight:bold;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><o:p></o:p></span></b></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >耐药所致的化疗失败及继而的复发转移是乳腺癌患者死亡的主要原因</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >探索乳腺癌耐药机制及发展治疗靶标是提高疗效、降低耐药风险及延长生存率的关键环节。目前肿瘤多药耐药机制已相继证明与</font>ABC(ATP-bindingcassette)<font face="宋体" >家族蛋白成员</font><font face="Times New Roman" >(ABCB1</font><font face="宋体" >、</font><font face="Times New Roman" >ABCC1</font><font face="宋体" >及</font><font face="Times New Roman" >ABCG2</font><font face="宋体" >等</font><font face="Times New Roman" >)</font><font face="宋体" >、化疗药物代谢途径改变、药物靶点突变失活、肿瘤干细胞等因素密切相关。逆转耐药的主要策略仍以抑制药物外排，即开发</font><font face="Times New Roman" >ABC</font><font face="宋体" >蛋白抑制剂为重点。虽然已选出少量先导化合物，但由于特异性、安全性及体内代谢等问题，仅有少数药物处于临床试验阶段。从新的角度探讨肿瘤耐药机制及发展治疗靶标成为当务之急。自噬与肿瘤发生、发展及治疗疗效密切相关。自噬指在饥饿、缺氧及能量应激状态下，细胞通过膜结构降解胞质细胞器和大分子的动态过程，其回收利用的降解产物能帮助细胞度过应激状态。研究表明化疗可以杀死大部分的肿瘤细胞，但少数细胞可通过提高自噬活性从逆</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >境中生存下来，一旦生长条件有利，细胞会恢复活力并导致肿瘤复发，是诱导肿瘤耐药并引起复发的重要原因。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >既往自噬研究多集中在细胞自噬基因</font>(autophgy-related gene,</span><i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-style:italic;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >Atg</span></i><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >)<font face="宋体" >和</font><font face="Times New Roman" >PI3K/AktmTOR</font><font face="宋体" >、</font><font face="Times New Roman" >Beclin-1</font><font face="宋体" >、</font><font face="Times New Roman" >HMGB1</font><font face="宋体" >、</font><font face="Times New Roman" >AMPK</font><font face="宋体" >等多条自调控通路。如相关研究表明</font><font face="Times New Roman" >HMGB1</font><font face="宋体" >可通过多种途径促进细胞自</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >噬</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的发生、发展，如细胞核内的</font>HMGB1<font face="宋体" >可通过调节热休克蛋白</font><font face="Times New Roman" >B1(heatshockproteinB1,HSPB1)</font><font face="宋体" >的表达调节自噬。在细胞浆内的</font><font face="Times New Roman" >HMGB1</font><font face="宋体" >主要是通过与自因子</font><font face="Times New Roman" >Beclin-1</font><font face="宋体" >结合，推动</font><font face="Times New Roman" >Beclin-1</font><font face="宋体" >与凋亡抑制因子</font><font face="Times New Roman" >Bel-2</font><font face="宋体" >的分离而促进</font><font face="Times New Roman" >Beclin-1</font><font face="宋体" >和</font><font face="Times New Roman" >&#8546;</font><font face="宋体" >型磷酸肌醇</font><font face="Times New Roman" >3</font><font face="宋体" >激酶</font><font face="Times New Roman" >(PI3K-ClassHI)/sp34</font><font face="宋体" >结合，从而激活自噬。细胞膜外的</font><font face="Times New Roman" >HMGB1</font><font face="宋体" >则主要通过与细胞膜晚期糖基化终产物受体</font><font face="Times New Roman" >(the receptor of advanced glycation endproducts.RAGE)</font><font face="宋体" >结合后激活其下属信号通路来增强自噬水平。</font><font face="Times New Roman" >HMGB1</font><font face="宋体" >与</font><font face="Times New Roman" >RAGE</font><font face="宋体" >结合后可以激活细胞外调节蛋白激酶</font><font face="Times New Roman" >(extracellular regulated protein kinases,ERK)</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >激活的</font>ERK<font face="宋体" >可以激活死亡相关蛋白激酶</font><font face="Times New Roman" >(death-associated protein kinase,DAPK)</font><font face="宋体" >使</font><font face="Times New Roman" >Beclin1</font><font face="宋体" >磷酸化</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >推动</font>Beclin-1<font face="宋体" >与</font><font face="Times New Roman" >Bcl-2</font><font face="宋体" >分离，调节细胞自噬的水平。同时</font><font face="Times New Roman" >HMGB1</font><font face="宋体" >与</font><font face="Times New Roman" >RAGE</font><font face="宋体" >结合后，也可以通过抑制</font><font face="Times New Roman" >mTORC1</font><font face="宋体" >的磷酸化激活，调节自噬的启动。</font><font face="Times New Roman" >HMGB1</font><font face="宋体" >在多种实体性肿瘤如肠癌、胰腺癌、乳腺癌、胆癌及造血系统恶性肿瘤中高表达，且与肿瘤的临床分型及肿瘤细胞生长、侵袭、转移密切相关。近年来研究证实</font><font face="Times New Roman" >HMGB1</font><font face="宋体" >与肿瘤细胞化疗耐药亦密切相关，同时多数研究认为</font><font face="Times New Roman" >HMGB1</font><font face="宋体" >可以通过调节自噬影响肿瘤细胞化疗耐药。鉴于</font><font face="Times New Roman" >HMGB1</font><font face="宋体" >与自噬的密切关系以及在肿瘤耐药机制中的关键作用，</font><font face="Times New Roman" >HMGB1</font><font face="宋体" >将成为逆转肿瘤多药耐药新的突破点，为肿瘤治疗带来新的</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >希望。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >然而肿瘤</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的发生、发展不仅取决于肿瘤细胞本身，还取决于肿瘤微环境。肿瘤微环境作为免疫应答和调节的中心，细胞因子、免疫球蛋白和免疫相关细胞均参加了肿瘤自噬和耐药的调控。如</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >IFN-</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >&#947;过表达具有抑制小鼠胃黏膜肿瘤发生的作用，并能诱导胃上皮细胞自噬，其机制与上调</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Beclin-1</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >表达有关。巨噬细胞游走抑制因子</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MIF</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >可促进肝癌细胞</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >LC3-</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >&#8544;转化为</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >LC3-</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >&#8545;，激活自噬诱发转移。糖基化终产物受体</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >RAGE</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >是细胞表面免疫球蛋白超家族的一员，其可通过激活</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >HMGB1</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >介导的自增加肿瘤细胞对化疗的耐药。此外，将肿瘤细胞与中性粒细胞、自然杀伤细胞共培养时，肿瘤细胞也出现了明显</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的自噬形态学改变，提示自</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >噬</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >可能作为一种肿瘤免疫微环境与肿瘤细胞之间交叉对话的媒介。然而目前有关肿瘤免疫微环境与自噬的关系研究尚不深人，包括巨噬细胞在内的免疫细胞如何启动自噬诱导肿瘤耐药，是通过什么样的具体机制，是否有临床治疗意义，目前的研究十分有限，值得在研究中进一步探索与求证，以此丰富肿瘤自噬功能的调控网络。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在对肿瘤耐药逆转剂进行探索的过程中，上市西药寥寥无几。五十多年的中西医结合临床实践表明，中药联合治疗一方面能够增强化疗药物的疗效，另一方面也提高患者对化疗的耐受性，并能减轻化疗的毒副作用，已经成为我国治疗肿瘤的一大优势，是开发耐药逆转剂的重要宝库。肿瘤患者化疗后，多有脾肾亏虚、气血受损的表现。从中医角度分析，化疗药物属于攻邪之品，容易导致机体肾虚血瘀，正气不足，引起肿瘤微环境急剧变化或能量供给不足，即刻诱导肿瘤细胞自我保护、发生自噬，提供其继续生长所需营养，使肿瘤细胞具有耐药性。因此，肾虚血瘀是导致肿瘤耐药的关键因素，自噬是肾虚血瘀肿瘤微环境下的主要产物，治疗应着重从整体出发，调整机体阴阳、气血、脏腑功能的平衡，由此补肾活血、提高免疫是中医药调节免疫微环境抑制自噬耐药的重要疗法。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >此部分研究中，为了探讨消癖颗粒的化学增敏作用，我们首先采用活细胞计数法检测消癖颗粒在非细胞杀伤浓度范围内对化疗药物紫杉醇的协同作用，研究结果显示</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒在</font>50&#181;g/mL<font face="宋体" >即可显著协同紫杉醇抑制乳腺癌细胞系</font><font face="Times New Roman" >MDA-MB-231</font><font face="宋体" >和</font><font face="Times New Roman" >MCF-7</font><font face="宋体" >的增殖和克隆形成。同时药物外排实验显示消癖颗粒施加后，可显著增加化疗药</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >物表柔比星的细胞内浓度，提示消癖颗粒可能通过抑制化疗药物外排达到化疗增敏的作用效果。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >自噬激活</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >是肿瘤细胞耐药的重要机制，为了探讨消癖颗粒对自</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >噬</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >活性的调控作用，首先采用自噬激活剂</font>Rapamycin<font face="宋体" >检测其对消癖颗粒化疗增敏活性的影响，细胞计数法显示</font><font face="Times New Roman" >Rapamycin</font><font face="宋体" >可显著削弱消癖颗粒的化学增敏作用，同时免疫蛋白印迹实验也提示消癖颗粒施加后，自</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >噬</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >标志蛋白</font>LC-3<font face="宋体" >和耐药蛋白</font><font face="Times New Roman" >ABCG2</font><font face="宋体" >表达水平降低，激光共聚焦实验也证实消癖颗粒作用后，紫杉醇诱导的自噬小体和自噬溶酶体的数量显著降低。在此基础上，免疫蛋白印迹、透射电子显微镜和溶酶体标记实验进一步证实消癖颗粒可显著抑制紫杉醇诱导的自噬活性。以上结果提示消癖颗粒可显著抑制化疗药物介导的乳腺癌细胞自噬活性增强，从而提高化疗敏感性。在前期实验基础上，拟探讨消癖颗粒主要靶标</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >对乳腺癌细胞自活性的影响。细胞计数法研究提示</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >上调后可显著降低乳腺癌细胞</font><font face="Times New Roman" >MDA-MB-231</font><font face="宋体" >的化疗敏感性，而其下调后可加强其化疗敏感性。激光共聚焦、免疫蛋白印迹联合透射电子显微镜提示</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >可正向诱导乳腺癌细胞自噬活性，同时上调耐药蛋白</font><font face="Times New Roman" >ABCG2</font><font face="宋体" >的表达水平，提示</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >是自噬调控通路中的重要靶点。为了探讨消癖颗粒对乳腺癌细胞表达</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >的影响，首先采用免疫蛋白印迹法检测发现消癖颗粒可剂量依赖性降低</font><font face="Times New Roman" >Rapamycin</font><font face="宋体" >或紫杉醇诱导的</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >表达，同时</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >上调可显著削弱消癖颗粒的化疗增敏作用，</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >上调后，消颗粒诱导的自抑制又重新增强，提示消癖颗粒通过抑制</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >介导的自活性增强化疗敏感性</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >体内实验采用裸鼠建立乳腺癌原位生长模型，消癖颗粒予以每日灌胃治疗，每</font>3<font face="宋体" >日观察乳腺癌体积和小鼠重量变化。研究结果显示消癖颗粒可显著增强紫杉醇的肿瘤抑制作用，而小鼠体重无显著变化。免疫组织化学染色提示消癖颗粒可显著降低肿瘤组织内</font><font face="Times New Roman" >CXCL1</font><font face="宋体" >、</font><font face="Times New Roman" >LC3</font><font face="宋体" >、</font><font face="Times New Roman" >HMGB1</font><font face="宋体" >及</font><font face="Times New Roman" >ABCG2</font><font face="宋体" >等自噬相关蛋白表达水平，同时进一步增强紫杉醇对细胞增殖抗原</font><font face="Times New Roman" >Ki67</font><font face="宋体" >的抑制作用。采用斑马鱼胚胎检测消癖颗粒体内应用安全性，研究结果显示消癖颗粒单独使用没有显著影响斑马鱼胚胎的孵出率、胚胎活性和致畸率，同时消癖颗粒和紫杉</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >醇联合应用也没有增加紫杉醇对胚胎的毒性，联合用药组孵出率、胚胎活性和致畸率无显著变化。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >综上所述，以自噬为切入点建立起宿主整体与肿瘤局部之间的共调节关系解析肿瘤微环境对肿瘤化疗耐药形成的作用和分子机制，为改善抗肿瘤药物耐药性开辟了一条完全不同的新道路，有助于阐释消癖方</font><font face="宋体" >“补肾活血”增强化疗敏感性的药理机制，为中西医结合防治肿瘤临床实践提供了科学证据，促进了中医药理论的科学转化。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.1000pt;mso-char-indent-count:2.0000;line-height:150%;" ><b><span style="mso-spacerun:'yes';font-family:楷体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-weight:bold;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >4.小结</span></b><b><span style="mso-spacerun:'yes';font-family:楷体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-weight:bold;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><o:p></o:p></span></b></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >通过本项目的研究，发现消癖颗粒主要作用机制为影响肿瘤微环境，结合细胞因子芯片和生物学功</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >能实验发现</font>TAMS/CXCL1<font face="宋体" >通路在介导消癖颗粒抑制乳腺癌发生、发展过程中发挥主要作用，消癖颗粒可通过</font><font face="Times New Roman" >TAMS/CXCL1</font><font face="宋体" >通路增强乳腺癌化疗敏感性，抑制乳腺癌干细胞干性，同时阻断转移</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >微环境形成</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >林毅教授认为正气亏虚是恶性肿瘤复发转移的根本病因，其主要因素包括</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >：</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >①肿瘤患者素体亏虚或禀赋不足。②癌毒炽盛导致正气消耗。③前期治疗攻伐过盛，导致机体正气损伤。&#9315;患者年老，肝肾亏虚，气血生化乏源，正气亏虚。正气亏虚导致患者免疫功能低下，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >使免疫细胞难以杀灭循环肿瘤细胞从而导致转移灶形成，因此扶正培本是改善转移微环境的第一要务。肾乃先天之本，而脾为后天之本，故健脾补肾法在调节患者机体免疫力，改善正气方面首当其冲。近现代中医学者把人体的功能活动及对外环境的适应能力、抗病祛邪能力及调节修复能力归属于</font><font face="宋体" >“正气”。正气抗御、清除有害异物</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(即人体内外邪气)和调节自身生理稳态的作用与现代医学免疫系统对机体“防御”“自稳”及“监视”等功能相契合。《素问&#183;宝命全形论》云</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >：</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >“人生有形，不离阴阳。”《素问&#183;生气通天论》云</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >：</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >“生之本，本于阴阳。”《素问&#183;生气通天论》</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >云：</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >“阴平阳秘，精神乃治”，认为人体健康是机体阴阳相互调节，对立中</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >取得动态平衡的结果。而机体识别</font><font face="宋体" >“自我”和排除“异已”维持生理稳态的免疫功能也是人体阴阳平衡的重要表现之一，受阴阳平衡规律的调节和支配，包括各种免疫细胞、分子等，它们既能促进免疫，又能反馈抑制，相互促进并约束。然正气充足是维持人体阴阳动态平衡的先决条件，平衡则健，失衡则病。中医药在数千年来积累了大量的临床经验，现代研究表明中医药可调节细胞因子的分泌及异常细胞信号的传导，促进效应细胞的增殖分化，重</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >塑机体</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Th1/Th2</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >和</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >M1/M2</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Times New Roman';
mso-hansi-font-family:'Times New Roman';mso-bidi-font-family:'Times New Roman';line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >平衡，增</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >强机体免疫功能。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在长期医疗实践中也发现传统中医药复方在协同化疗、延长无进展生存期、延长生存时间、降低癌症患者手术后的复发和转移率、稳定瘤体、提高患者生存质量等方面表现突出，是中医学对国际肿瘤治疗策略发展的重要贡献和创新源泉。但中医药复方在癌症治疗中的核心地位仍然长期没有受到重视和认可，究其原因，主要在于以下几点：</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >①中药复方缩小瘤体效果不明显，经长期临床实践，其疗效优势主要在于稳定瘤体，协同放化疗提高疗效并抑制肿瘤的恶性进展，但在相应研究中缺乏相应的方法学和评价指标。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >②既往中药复方的机制研究从分子细胞等微观角度开展，不符合中医“整体观”医学的特色，导致与临床疗效相关的机制研究十分薄弱，机理不明确也使得中药复方临床循证研究结果难以获得国际认可。③中药复方缺乏精准化用药的依据，宽泛化用药降低了有效率。因此，迫切需要建立在中医整体观念指导下的中药复方研究方法体系，开展与临床疗效相结合的机制研究，明确中药复方中的抗癌活性成分并优化处方，探索中药复方精准化用药依据促进中药复方治疗恶性肿瘤国际性标准及现代化发展通道。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >大量临床及基础研究表明中医药起效的根本机制在于整体调控宿主</font><font face="宋体" >——</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >肿瘤微环境，尤其是对肿瘤实质中免疫微环境的调控。多种抗肿瘤中药复方均可从激活单核巨噬细胞、调整</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >T</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞免疫平衡、提高树突状细胞抗原提呈能力及逆转免疫逃逸等方面增强患者的免疫功能，从而达到抑制肿瘤耐药和转移的目的，而且具有多环节、多靶点和整体调控的特点。然而中医药对肿瘤免疫耐药关键信号的调控机制尚不清楚，同时由于化学成分复杂，大部分中药复方面临分子机制不清、物质基础不明等关键问题，进一步解析中医药调控肿瘤免疫耐药信号抑制肿瘤耐药和转移的分子机制和物质基</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >础具有重大意义。因此，开展多学科协同攻关，中医理论与生物规律相结合、临床研究与基础研究相结合、中医研究与中药研究相结合，建立中医药标准化研究架构在推进中医药现代化和国家化的过程中至关重要。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >本研究的开展以免疫微环境调控机制及分子靶标为桥梁，结合中医药整体观及调整微环境平衡独特性，体现了肿瘤发生发展过程中正与邪的辩证关系，突出了肿瘤发生或转移是肿瘤局部与宿主整体之间相互作用的过程，阐释了中西医结合防治肿瘤的合理性及优势，为中医药参与肿瘤多学科综合治疗提供了理论依据和数据支持。最为重要的是，本研究对林毅教授</font></span><span style="mso-spacerun:'yes';font-family:'Times New Roman';mso-fareast-font-family:宋体;
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >从医</font>60<font face="宋体" >年为广</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >大女性健康奉献的心血精华进行了科学论证和理论升华，体现了林毅教授所倡导的</font><font face="宋体" >“辨病为体，辨证为用，病证结合，标本兼治”的核心思想</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >为进一步挖掘和弘扬林毅教授的大医之道打下了坚实基础。在此衷</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >心感谢林毅教授在学术、思想、事业和生活中无微不至的关怀和教导，导师对中医药事业的热爱、执着、自信和推崇精神将永远激励我们不断挖掘中医药理论精华，发现自然生物学规律，以</font><font face="宋体" >“传承精华，守正创新”为指导思想，充分发挥中医药防病治病的独特优势和作用，为建设健康中国、实现中华民族伟大复兴的中国梦贡献力量。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  align=right  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;text-align:right;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >（王志宇</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >王能</font> </span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >司徒红林</font> </span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >整理</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >）</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.1000pt;mso-char-indent-count:2.0000;line-height:150%;" ><b><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-weight:bold;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >参考文献</font></span></b><b><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-weight:bold;font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><o:p></o:p></span></b></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[1]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >司徒红林</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >,林毅,陈前军,等.中药癌复康对乳腺癌术后化疗患者生存质量的影响[</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >J</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >].广州中医药大学学报,2005,22(1):26-29.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[2]司徒红林,陈前军,欧爱华,等.乳腺癌术后患者生存质量影响因素的累加Logit回归模型分析[</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >J]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.中国现代实用医学杂志,2005.4(8):44-47.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[3]陈前军,张蓉,司徒红林,等.康复灵胶囊对乳腺癌多药耐药基因p170、GST-&#960;影响的临床研究[</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >J]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >中国药房</font>,2008,19(21):1650-1652.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[4]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >朱华宇</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >,钟少文,李玉洁,等,中药癌复康对重症联合免疫缺陷鼠人乳腺癌肺转移及免疫重建的影响[J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.现代中西医结合杂志,2016.25(15):1597-1599</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >,</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >1603.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[5] SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2019[J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >. CA Cancer JClin.2019,69(1):7-34.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[6]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >DESANTIS CE, MA J, GAUDET MM, et al. Breast cancer statistics, 2019[J]. CACancer J Clin.2019,69(6):438-451.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[7] NGUYEN LV, VANNER R, DIRKS P, et al. Cancer stem cell: an evolvingconcept[J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.Nat Rev Cancer, 2012.12(2):133-143.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[8] LIU S, WICHA MS. Targeting breast cancer stem cells[J]. J Clin Oncol. 2010.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >28(25):406-412.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[9]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >PROSPERI JR, GOSS KH.A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancerI. Curr Drug Targets. 2010, 11(9):1074-1088</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[10]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MICHAELSON JS, LEDER P. Beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland,. 0ncogene, 2001, 20(37):5093-5099.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[11]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >SUBRAMANIAM D, RAMALINGAM S, HOUCHEN Cw, et al. Cancer stem</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >cells: a novel paradigm for cancer prevention and treatment</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J]. Mini Rev MedChem.2010 May, 10(5):359-371.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >12]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CRISCITIELLO C, CURIGLIAN0 G. Immunotherapeutics for breast cancer</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J].Curr Opin Oncol. 2013, 25(6):602-608.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[13]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >COMEN EA. Tracking the seed and tending the soil: evolving concepts in</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >metastatic breast cancerl</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >. Discov Med. 2012 Aug, 14(75):97-104.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[14]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >EMENS LA. Breast cancer immunobiology driving immunotherapy: vaccinesand immune checkpoint blockade</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >]. Expert Rev Anticancer Ther. 2012 Dec,12(12):1597-1611.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[15]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >GASPARRI ML, BELLATI F, NAPOLETANO C, et al. Interaction between Tregcells and angiogenesis: a dark double track</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >. Int J Cancer. 2013;132(10):2469.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >16]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Y&#218; X, LI H, REN X. Interaction between regulatory T cells and cancer stemcells</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.Int J Cancer. 2012,131(7):1491-1498.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[17]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >JINUSHI M, CHIBA S, YOSHIYAMA H, et al. Tumor-associated maerophagesregulate tumorigenicity and anticancer drug responses of cancer stem/initiatingcells</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >. Proe Natl Acad Sci USA. 2011, 108(30):12425-12430.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[18] YANG J, LIA0 D, CHEN C, et al.Tumor-associated macrophages regulatemurine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2signaling pathway[J]. Stem Cells. 2013, 31(2):248-258.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[19] MA HD, DENG YR, TIAN Z, et al. Traditional Chinese medicine and immuneregulation[</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >J</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >]. Clin Rev Allergy lmmunol. 2013, 44(3):229-241.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[20] </font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >LIN H, LU J, ZHANG Y. Developments in cancer prevention and treatmentusing traditional Chinese medicine[</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >J</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >]. Front Med. 2011.5(2):127-133.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[21]陆德铭.实用中医乳腺病学[M].上海:上海中医学院出版社,1993.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[22]洪宋贞,蔡芳英,朱华宇,消癖口服液系列治疗乳腺增生病的疗效小.实用</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >医学杂志</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >,2007.23(20):3276-3277.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[23] WANG N, ZHENG Y, GU J, et al. Network-pharmacology-based validation ofTAMs/CXCL-1 as key mediator of XlAOPl formula preventing breast cancerdevelopment and metastasis</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >. Scientific Reports, 2017, 7(1):14513.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[24] WANG S, LIU X, HUANG R, et al. XIAOP formula inhibits breast caneer stemcells via suppressing TAMs/CXCLl pathway[</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >J</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >]. Frontiers in Pharmacology,2019,10: 1371.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[25]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >HARBECK N, GNANT M. Breast cancer</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >. Lancet. 2017,389(10074):1134-1150</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >.</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[26] BIDARD FC, PROUDHON C, PIERGA JY. Circulating tumor cells in breastcancer</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J]. Mol Oncol. 2016 ,10(3):418-430.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[27] RIGGI N, AGUET M, STAMENKOVIC I. Cancer metastasis: a reappraisal of itsunderlying mechanisms and their relevance to treatment[J]. Annu Rev Pathol.2017, doi:10.1146/annurev- pathol-020117-044127.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[28]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >GILES AJ, REID CM, EVANS JD, et al. Activation of hematopoietic stem/progenitor cells promotes immunosuppression within the pre-metastaticnichel</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >]. Cancer Res. 2016, 76(6):1335-1347.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[29]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >URSINI-SIEGEL J, SIEGEL PM. The influence of the pre-metastatic niche onbreast cancer metastasis</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J]. Cancer Lett.2016,380(1):281-288.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[30]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >COSTA-SILVA B, AIELLO NM,OCEAN AJ, et al. Pancreatic eancerexosomes initiate pre-metastatic niche formation in the liver</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >. Nat Cell Biol.2015,17(6):816-826.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[31]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >OIAN BZ, POLLARD JW.Macrophage diversity enhances tumor progression</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >and metastasis[J]. Cell. 2010, 141(1):39-51. </span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[32]王能,张奉学,陈建萍,等,中医药干预恶性肿瘤转移新模式--靶向调控预转移龛</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.环球中医药,2019,12(3):464-469.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[33]张健,张淑贤.中医传舍理论与肿瘤转移</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J].中国中医基础医学杂志.1999.5(6):4-6.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[34]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >魏华民</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.华宝金.中医治疗肿瘤转移新模式--转移前微环境干预</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.世界中医药.2016.11(10):2204-2208.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[35]叶乃菁,刘宣,李琦.癌毒转移的中医理论探讨[</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >J</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >].中医杂志.2014.55(3):185-188.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[36]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >王志学</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.癌转移的中医病机及治疗对策</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.国医论坛,1999,14(4):18-19. </span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[37]华何与,杨运高,张红栓.论气虚血瘀与肿瘤转移町</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >].中国中医基础医学杂</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >志</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.2005.11(8):564-565</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >.</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[38]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >程海波</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.癌毒病机理论探讨</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.中医杂志,2014,55(20):1711-1714. </span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[39]李琦玮,于明薇,王笑民.癌毒理论研究现状</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.中医杂志,2015,56(4):347-354.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[40]王志学,肿瘤血瘀证与转移及活血化瘀法抗转移治疗探讨</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.中医药研究</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >,</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >1999.15(6): 9-10.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[41]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >崔应珉</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >,邓为,刘明.恶性肿瘤及转移从痰论治</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.中国中医药报,2009,4:1-3. </span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[42]贾小强,黄乃健,邱辉忠.恶性肿瘤转移的中医病机研究思路和策略</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.中医药临床杂志,2005.17(1):60-61.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[43]吴皞,王瑞平,陈雪,等,基于肿瘤微环境学说的中医抗癌策略探讨</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.四川中医.2018.36(6):50-53.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[44] LIU J, WANG S, ZHANG Y, et al. Traditional Chinese medicine and cancer:History, present situation, and development</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >」</font>. Thorac Cancer. 2015, 6(5):561-569</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[45]李金玉,李金耀,张富春,中药抗肿瘤免疫调节机制研究进展J].时珍国医国药,2016,27(7):1705-1707.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[46]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >W00 SM1,CH0I YK, CH0 SG, et al. A new herbal formula, KSG-002suppresses breast cancer growth and metastasis by targeting NF-kB-dependentTNF a production in macrophages</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >. Evid Based Complement Alternat Med2013.2013:728258.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[47] ZHU X, ZHOU Y, XU Q, et al. Traditional Chinese medicine Jianpi Bushentherapy suppresses the onset of pre-metastatic niche in a murine model ofspontaneous lung metastasis[</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >J]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >. Biomed Pharmacother.2017,86:434-440.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[48]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >ZHENG Y, WANG N, WANG S, et al. XIAOP[ formula inhibits the pre-metastatie niche formation in breast cancer via suppressing TAMs/CXCL1signaling</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J].Cell Communication & Signaling, 2020, 18(1): 48.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[49]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >WANG N,LU W.ZHENG Y, et al. CXCLl derived from tumor-associated</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >macrophages promotes breast cancer metastasis via activating NF-k B/SOX4signaling[J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >. Cell death & Disease, 2018, 9(9):880. </span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[50]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MCDONALD ES,CLARK AS, Tchou J, et al. Clinical Diagnosis and</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Management of Breast Caneer</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >]. Journal of nuclear medicine : officialpublication, Society of Nuclear Medicine 2016, 57 Suppl 1:9-16.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[51]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >O’REILLY EA, GUBBINS L, SHARMA S, et al. The fate of chemoresistancein triple negative breast cancer (TNBC)[J]. BBA clinical 2015. 3:257-275.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[52]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >KUCZYNSKI EA, SARGENT DJ, GROTHEY A, et al. Drug rechallenge andtreatment beyond progression-implications for drug resistance</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >. Naturereviews Clinical oncology, 2013,10(10):571-587.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[53]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MAH LY, RYAN KM. Autophagy and cancer[J]. Cold Spring Harbor</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >perspectives in biology, 2012,4(1):a008821.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >54]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >KONDO Y, KANZAWA T, SAWAYA R, et al. The role of autophagy in cancerdevelopment and response to therapy</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >, Nature reviews Cancer, 2005,5(9):726--734.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[55]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >OEHADIAN A.KOIDE N, HASSAN F, et al. Differential expression of</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >autophagy in Hodgkin lymphoma cells treated with various anti-cancer drugs</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >].Aeta medica Indonesiana, 2007,39(4):153-156.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[56]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >LOTZE MT, TRACEY KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >. Nature reviews lmmunology2005.5(4):331-342.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[57]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Muller S, Scaffidi P, Degryse B, et al. New EMBO members’ review: thedouble life of HMGBl chromatin protein: architectural factor and extracellularsignal[</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >J]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >. The EMBO journal, 2001.20:4337-4340.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[58]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XU T, JIANG L, WANG Z. The progression of HMGBl-induced autophagy in</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >cancer biology</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >]. OncoTargets and therapy, 2019,12:365-377.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[59] TANG D, LOZE MT, ZEH HI, et al. The redox protein HMGBl regulates celldeath and survival in cancer treatment[</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >J]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >, Autophagy, 2010,6(8):1181-1183.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[60]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MATHEW R.KARANTZA-WADSWORTH V, White E. Role of autophagy in</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >cancer</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >. Nature reviews Cancer, 2008,7(12):961-967.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[61] JINUSHI M, CHIBA S, YOSHIYAMA H, et al. Tumor-associated maerophagesregulate tumorigenicity and anticancer drug responses of cancer stem/initiatingcells</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >. Proceedings of the National Academy of Sciences of the United Statesof America 2011,108(30):12425-12430.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[62]刘杰民,纪云西,蒋历,等.细胞自噬是探索中医药微观机制的新思路</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >J</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.时珍</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >国医国药</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.2013.24(2):425-426.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[63]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >邱晓</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >,李学涛,居瑞军,等,中药“扶正固本”与化疗药联合抗肿瘤的研究进展</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >],世界中西医结合杂志,2018,13(11):1615-1619.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >[64]</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >WANG N. YANG B.GULIZEBA MUHETAER.et al. XlAOPl formula promotesbreast cancer chemosensitivity via inhibiting CXCLl/HMGBl-mediated autophagy</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >[J]</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.Biomedicine & Pharmacotherapy, 2019, 120: 109519.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p></div><!--EndFragment--></body></html>